Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
about
Rivastigmine for Alzheimer's diseaseAnti-dementia medications: current prescriptions in clinical practice and new agents in progressEffects of medicinal plants on Alzheimer's disease and memory deficits.Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.Morphology-based mammalian stem cell tests reveal potential developmental toxicity of donepezil.Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?Isolation, crystal structure determination and cholinesterase inhibitory potential of isotalatizidine hydrate from Delphinium denudatum.Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Expression and Function of the Cholinergic System in Immune Cells.Risk of pneumonia in new users of cholinesterase inhibitors for dementiaSynthesis and anticholinesterase activity and cytotoxicity of novel amide derivatives.Synthesis and biological evaluation of some pyrazoline derivatives bearing a dithiocarbamate moiety as new cholinesterase inhibitors.Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation.Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.Rivastigmine and Parkinson dementia complex.Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease.Profiling donepezil template into multipotent hybrids with antioxidant properties.Phytochemicals from Dodonaea viscosa and their antioxidant and anticholinesterase activities with structure-activity relationships.Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization.A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium.Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation
P2860
Q24241686-BEFF91F9-0AC9-4E83-8ADD-AA743C7883F4Q26795400-7A329D92-87F1-4FB6-8A2C-2268B1D16EE9Q33702630-1CF6F995-75F0-49E5-96E3-CD98CA4AE78AQ36226630-A91BD375-0094-4083-9E53-F79FAFD915F9Q37895257-2B9B11B8-EB8F-43EA-AFE8-F05B5E81E119Q38647822-0FB3FC18-4087-427D-BD19-CE2410DB1739Q38951854-40D0A3F2-ACEF-4BED-B169-82CD649CC1F1Q38962792-B4A13C35-95A7-4372-82A6-0B09C3B92296Q39052599-AD3F0229-2333-420E-826F-FC47AE16493CQ39196662-657B3B67-F6C1-4F6E-96E5-AA2363C8EF15Q39415447-2AE696C5-86D2-449A-B453-796C436BA39DQ41440417-E6EC1660-DAA1-449F-BDE8-8443B80622D7Q41509727-19E1CD9F-C655-4F7C-AB69-F60DD4DCF419Q42804221-1536ADCC-431D-45B6-A18E-9091E8BBC0E1Q42825770-DA94F84F-1738-47A6-8DBB-2520E4EBBB5FQ44014924-9A4B0B20-B91F-4B4F-ADD0-70C87D88F3D4Q45892584-D2381A0F-8C3E-40A4-A98C-1C80D2C6B20BQ48209581-6F37FF4D-D79C-4E91-B9E5-356FB6FE1559Q49643940-5D48FA06-116A-4E5C-90C4-2877073BFAE8Q50328399-09FCFB6D-D379-47C8-ABDB-07C24CF25BE9Q51109990-E85CD542-6CE0-4424-8D46-2506EEC3D4C3Q52660268-FA310C77-348D-416A-A456-EE7D77C3A81FQ53180352-F2178DB6-F22F-4F45-B690-7C1960822BCFQ53386775-8871F4BD-8312-4CD3-B36E-DCCC4F8466C0Q53460577-0C2A4825-EDC3-4C2A-9281-15ADF9D37D87Q55042429-957A3C87-3286-47A5-8930-230303998016Q58700158-D2409314-0387-4935-98B7-47653985F0D3
P2860
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cholinesterase inhibitors for ...... e:: getting on and staying on.
@en
type
label
Cholinesterase inhibitors for ...... e:: getting on and staying on.
@en
prefLabel
Cholinesterase inhibitors for ...... e:: getting on and staying on.
@en
P2860
P1476
Cholinesterase inhibitors for ...... e:: getting on and staying on.
@en
P2093
George T Grossberg
P2860
P304
P356
10.1016/S0011-393X(03)00059-6
P577
2003-04-01T00:00:00Z